Industry Odisha Bureau, Jul 27: When Americans fill prescriptions at corner pharmacies, they’re almost certainly handling pills manufactured thousands of miles away. Generic medicines account for roughly 90% of all drug prescriptions in the United States, and India supplies nearly half of those by volume a quiet but fundamental reality of modern healthcare that few patients ever consider.
That arrangement now faces its greatest threat in decades.
Last month, President Trump announced a tariff plan designed to upend decades of pharmaceutical supply-chain architecture: 100% duties on imported generics after two years, escalating to 200% after a third year, coupled with penalties for companies that fail to establish US manufacturing capacity on Washington’s timeline. The goal is straightforward drag drug production back from overseas, especially from India, which accounts for over a third of America’s pharmaceutical imports.
But reshaping global pharmaceutical supply chains rarely unfolds according to political schedules.
The economics reveal the central tension. Generic drug production operates on razor-thin margins, making India’s massive scale roughly $9.7 billion in annual US exports the primary profit engine for companies like Dr Reddy’s, Cipla, and Lupin, which derive 30 to 50 percent of revenues from American markets. Yet the US has spent decades shedding low-cost manufacturing capacity, creating a structural disadvantage that tariffs alone cannot quickly erase.
Constructing a modern pharmaceutical facility requires a minimum of two years before production begins, followed by 12 to 15 months of FDA inspections and regulatory approvals a timeline that makes Trump’s two-year threshold appear aspirational rather than achievable. Add the reality that domestic production of low-margin generics would be economically unviable for most drugmakers, and the reshoring dream becomes considerably more complicated than the rhetoric suggests.
Some companies occupy a privileged position. Cipla already manufactures 35 to 40 percent of its US-bound products domestically, while Lupin and Aurobindo have announced expansion plans. Others are exploring alternatives: Dr Reddy’s and competitors are evaluating technology transfers and partnerships with US manufacturers, though such arrangements face obstacles in a market as vast and price-sensitive as America’s.
Even so, observers widely expect that tariff implementation would ultimately force drugmakers to absorb costs by raising prices on US consumers the very opposite of Trump’s stated goal of reducing medicine costs.
The experience of the previous administration offers clues about how this unfolds. Earlier tariff threats against pharmaceutical companies functioned as negotiating leverage rather than policy reality, spurring commitments to domestic investment while negotiations continued behind closed doors. A “most favoured nation” pricing initiative ran parallel, aimed at aligning US drug prices with international markets.
The smaller and mid-sized Indian pharmaceutical exporters, lacking geographic diversification, face the most acute vulnerability. Larger rivals are hedging through global expansion: Sun Pharmaceutical’s acquisition of Organon opens doors across China and more than a dozen additional markets where manufacturing footprints remain limited.
The pharmaceutical industry awaits bilateral clarification, hoping negotiated settlement arrives before tariffs impose the difficult choice between reshoring at economic loss or exiting America’s vast but brutally competitive market. What appears certain is this: India’s dominance over affordable generic supply has become too central to American healthcare to dismantle overnight regardless of what policy intentions suggest.
